CANSOUL Invests in SYNBIOTIC for Strategic Industry Growth

CANSOUL, a specialized cannabis and hemp equity fund, has acquired a stake in SYNBIOTIC SE. This strategic investment marks the start of a long-term partnership, highlighting SYNBIOTIC's diversified business model. The acquisition was made through a cash capital increase, signifying CANSOUL's confidence in SYNBIOTIC's market potential.

CANSOUL's investment approach spans the global hemp and cannabis value chain, focusing on early-stage trends in infrastructure, patents, and licenses. SYNBIOTIC's strong differentiating factors, including an import license and GMP manufacturing authorization, make it an appealing opportunity. The company also boasts a technological edge with its cold plasma sterilization process.

Both organizations recognize the significant developments in medical cannabis and industrial hemp markets in Germany. Despite optimistic market potential, they foresee commercial recreational cannabis use materializing over the next five to ten years. Meanwhile, medical cannabis and industrial hemp remain the key growth drivers.